The prevalence of rheumatic immune-related adverse events in 524 patients with cancer who received immune checkpoint inhibitors was 6.6%, according to a single-center observational study published in Annals of the Rheumatic Diseases.READ MORE

From The Journal

The potential impact of CAR-T therapies should not be underestimated, nor should their complexity, which is why a broader understanding of stakeholder knowledge and perception may be critical to their adoption and use. READ MORE
October 18-20 marked the annual Association of Community Cancer Centers (ACCC) National Oncology Conference. Key opinion leaders convened in Nashville, Tennessee to share cutting-edge ideas, strategies, and practical takeaways for transforming patient care in cancer programs. READ MORE
Journal of Clinical Pathways spoke with Editorial Advisory Board member Ayman Elfiky, MD, MSc, MPH, about how clinical pathways are used at Dana-Farber Cancer Institute (Boston, MA). READ MORE
New drugs for orphan and rare diseases have the potential to positively impact the lives of patients where historically few or no treatments had been available to manage the disease. READ MORE